Inquiry Basket
Loading ......
Bovine Leukemia Virus (BLV), a member of the Retroviridae family and Deltaretrovirus genus, is a significant pathogenic agent that infects cattle globally, causing enzootic bovine leukosis (EBL)—the most common neoplastic disease affecting cattle populations. First identified in the 1960s, BLV shares close genomic and biological similarities with the human T-cell leukemia virus type 1 (HTLV-1), making it a valuable model for studying retroviral oncogenesis and persistent infections. While most infected cattle remain asymptomatic carriers, a subset develops progressive lymphoproliferative disorders, leading to substantial economic losses in the dairy and beef industries due to reduced milk production, reproductive failures, and premature culling of affected animals.
Figure 1. Structure of Bovine Leukemia Virus.( Marawan, Marawan A., et al. 2021)
Bovine Leukemia Virus (BLV) is a deltaretrovirus that infects cattle worldwide, causing significant economic losses in the dairy and beef industries. As the etiological agent of enzootic bovine leukosis (EBL), BLV is characterized by its ability to induce persistent lymphocytosis (PL) and, in a subset of infected animals, malignant B-cell lymphomas. Despite decades of control efforts in some regions, BLV remains highly prevalent across the globe, particularly in countries without comprehensive eradication programs. Beyond its agricultural impact, BLV has garnered attention for its potential zoonotic implications, as studies have suggested possible associations with human breast cancer, though this remains a subject of ongoing scientific debate.
BLV belongs to the genus Deltaretrovirus within the family Retroviridae. It is closely related to the human T-cell leukemia virus (HTLV), sharing a similar genetic organization and pathogenic mechanism. The virus is an enveloped virus with a single-stranded, positive-sense RNA genome approximately 8.5 kilobases in length. Upon infection, BLV reverse transcribes its RNA genome into double-stranded DNA, which then integrates into the host genome as a provirus. Unlike acute transforming retroviruses, BLV does not carry an oncogene; instead, it induces oncogenesis through chronic immune stimulation and the activity of its regulatory proteins. The proviral genome contains the canonical gag, pol, and env genes, as well as a unique region at the 3' end known as the X region. This X region encodes several regulatory and accessory proteins essential for viral replication and pathogenesis, most notably Tax and Rex.
BLV infects primarily cattle, but it can also infect sheep, goats, and water buffalo experimentally or naturally. In cattle, the virus is most commonly transmitted through horizontal routes involving infected lymphocytes. Major transmission pathways include:
Notably, BLV is not transmitted via casual contact or aerosol; cell-to-cell transmission is the predominant mode, requiring direct transfer of infected lymphocytes. This tropism for B-cells is central to its pathogenesis.
BLV infection is characterized by a prolonged clinical latency. The majority of infected cattle (approximately 70%) remain asymptomatic aleukemic carriers with very low proviral loads. About 30% develop persistent lymphocytosis (PL), a benign but marked increase in circulating B-lymphocytes. Only a small fraction (1–5% of infected animals) progress to develop enzootic bovine leukosis (EBL), a fatal B-cell lymphoma that can affect lymph nodes, heart, abomasum, and other organs.
The pathogenesis of BLV is driven by the viral regulatory protein Tax, which functions as a transcriptional activator of both viral and cellular genes. Tax promotes the proliferation of infected B-cells and disrupts key tumor suppressor pathways, including p53 and Rb. Over decades of infection, the accumulation of genetic lesions and chronic antigenic stimulation eventually lead to clonal expansion and malignant transformation.
The oncogenic potential of BLV is primarily driven by the regulatory proteins encoded in the X region. These proteins manipulate host cell signaling, proliferation, and survival pathways, representing critical molecular targets for intervention.
| Key Molecular Targets | Details |
| NF-κB pathway | Tax constitutively activates both canonical and non-canonical NF-κB signaling, leading to sustained B-cell proliferation and survival. This is achieved through interactions with IKK complex components, promoting phosphorylation and degradation of IκB. |
| CREB/ATF pathway | Tax binds to CREB and enhances transcription from the viral LTR and certain cellular promoters. |
| Apoptosis inhibition | Tax upregulates anti-apoptotic factors such as Bcl-xL and downregulates pro-apoptotic molecules, promoting the survival of infected cells. |
Diagnosis of BLV relies on serological detection of antibodies against viral structural proteins, primarily through ELISA or agar gel immunodiffusion (AGID). PCR-based methods are used to quantify proviral load, which correlates with transmission risk.
Control strategies vary by region. Some countries, including many in Europe, have implemented successful eradication programs based on test-and-cull policies. In regions where eradication is not feasible, management focuses on reducing transmission through:
No commercial vaccine is currently available against BLV, although experimental vaccines have shown limited efficacy.
Bovine Leukemia Virus is a globally significant pathogen that exemplifies the complex interplay between viral persistence, immune evasion, and oncogenesis. Its study has not only informed veterinary control programs but has also provided valuable insights into the mechanisms of retrovirus-induced leukemia, particularly through the actions of the Tax and Rex proteins. While eradication is feasible in resource-rich settings, most affected regions continue to manage the virus through biosecurity measures. The development of effective vaccines and a clearer understanding of BLV's zoonotic potential remain critical priorities for future research.
Reference
| Target | Cat. No. | Product Name | Host | |
| BLV | DAG-WT766 | Recombinant Bovine Leukemia Virus gp51 | Insect cells | Inquiry |
| MLV gag | DAGA-3637 | Recombinant Protein AKV murine leukemia virus gag, Mammalian cell | Mammalian cells | Inquiry |
| MLV gag | DAGA-3638 | Recombinant Protein AKV murine leukemia virus gag, E.coli | E. coli | Inquiry |
| MLV gag | DAGA-3639 | Recombinant Protein AKV murine leukemia virus gag, Baculovirus | Baculovirus | Inquiry |
| Adoxophyes honmai nucleopolyhedrovirus VCATH | DAGA-3459 | Recombinant Protein Adoxophyes honmai nucleopolyhedrovirus VCATH, E.coli | E. coli | Inquiry |
Loading ......
